We are live on ! Find out more
TRML

Tourmaline Bio
TRML

Delisted

TRML was delisted on the 27th of October, 2025.

Back to rankings

54 hedge funds and large institutions have $50.6M invested in Tourmaline Bio in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more capital invested

Capital invested by funds: $27.5M → $50.6M (+$23.1M)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 53 → 54 (+1)

0.02% more ownership

Funds ownership: 6.43% → 6.46% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
18
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$3.18M
2
Citigroup
Citigroup
New York
+$1.4M
3
WSL
Western Standard LLC
California
+$967K
4
Morgan Stanley
Morgan Stanley
New York
+$431K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$210K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.09M
2
AG
Artal Group
Luxembourg
-$1.9M
3
Two Sigma Investments
Two Sigma Investments
New York
-$127K
4
CCM
CAAS Capital Management
New York
-$92K
5
IA
IFP Advisors
Florida
-$89K
Name Holding Trade Value Shares
Change 		Change in
Stake
Blackstone Inc
1
Blackstone Inc
New York
$15.2M – – –
Viking Global Investors
2
Viking Global Investors
Connecticut
$6.18M – – –
QUSVM
3
Qiming U.S. Ventures Management
Washington
$5.51M – – –
BCM
4
BML Capital Management
Indiana
$3.63M +$3.18M +192,948 New
EAM
5
Eventide Asset Management
Massachusetts
$2.93M – – –
BlackRock
6
BlackRock
New York
$2.19M +$108K +6,532 +6%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.11M +$121K +7,314 +7%
Citadel Advisors
8
Citadel Advisors
Florida
$1.96M -$4.09M -247,701 -70%
AG
9
Artal Group
Luxembourg
$1.72M -$1.9M -115,000 -56%
CAM
10
Cormorant Asset Management
Massachusetts
$1.69M – – –
Citigroup
11
Citigroup
New York
$1.6M +$1.4M +84,973 +369,448%
WSL
12
Western Standard LLC
California
$1.1M +$967K +58,648 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$767K +$66.3K +4,019 +11%
State Street
14
State Street
Massachusetts
$667K +$29.8K +1,809 +5%
LCM
15
Laurion Capital Management
New York
$561K – – –
Morgan Stanley
16
Morgan Stanley
New York
$516K +$431K +26,130 +1,959%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$447K +$210K +12,710 +114%
Northern Trust
18
Northern Trust
Illinois
$307K -$5.46K -331 -2%
BCM
19
Bridgeway Capital Management
Texas
$240K -$60.2K -3,650 -22%
MAM
20
Marquette Asset Management
Minnesota
$191K +$36.3K +2,200 +28%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$110K – – –
Renaissance Technologies
22
Renaissance Technologies
New York
$104K +$57.1K +3,460 +166%
VFA
23
Values First Advisors
Tennessee
$99.4K +$21.5K +1,301 +33%
Charles Schwab
24
Charles Schwab
California
$94.9K – – –
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$65K +$330 +20 +0.6%
1
2 3

TRML Hedge Fund Activity: Q1 2023 in Review

54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q1 2023, worth a combined $50.6M — up 84% from $27.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TRML positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 13 trimmed.

The largest buyer was BML Capital Management, opening a new position worth an estimated $3.18M. The largest seller was Citadel Advisors, cutting an estimated $4.09M.

  • 54 institutional investors held Tourmaline Bio (TRML) as of Q1 2023, up from 53 in Q4 2022.
  • Funds reported $50.6M of Tourmaline Bio stock for Q1 2023, up 84% quarter-over-quarter.
  • 9 funds opened new Tourmaline Bio positions in Q1 2023 and 8 closed out, a net change of +1 holder.
  • The largest Tourmaline Bio buyer in Q1 2023 was BML Capital Management, an estimated $3.18M added.
  • The largest Tourmaline Bio seller in Q1 2023 was Citadel Advisors, an estimated $4.09M sold.

Based on aggregated 13F filings for Q1 2023.